Regulus Therapeutics reported $57.93M in Current Assets for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Alnylam Pharmaceuticals ALNY:US $ 2589.68M 218.9M
AstraZeneca AZN:LN 22.65B 3.6B
Astrazeneca AZN:US 22.65B 3.6B
Biogen BIIB:US $ 7915.9M 59.4M
Celldex Therapeutics CLDX:US $ 390.7M 20.14M
Gilead Sciences GILD:US $ 12629M 2143M
GlaxoSmithKline GSK:LN 28.99B 10.31B
Intercept Pharmaceuticals ICPT:US $ 477.35M 24.94M
Intrexon XON:US $ 154.94M 1.69M
Lexicon Pharmaceuticals LXRX:US 88.43M 490K
Ligand Pharmaceuticals LGND:US $ 276.07M 188.68M
Merk MRK:US $ 31184M 918M
Omeros OMER:US $ 210.22M 37.67M
Regulus Therapeutics RGLS:US $ 57.93M 7.3M
Sangamo Biosciences SGMO:US $ 340.06M 58.7M
Spectrum Pharmaceuticals SPPI:US $ 93.18M 10.77M
Takeda 4502:JP Y 2593642M 115749M
Vital Therapies VTL:US $ 115.88M 10.89M
YTE INCY:US $ 3288.09M 169.42M